Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q14563
UPID:
SEM3A_HUMAN
Alternative names:
Semaphorin III
Alternative UPACC:
Q14563
Background:
Semaphorin-3A, also known as Semaphorin III, plays a crucial role in the development of the olfactory system and the neuronal control of puberty. It induces the collapse and paralysis of neuronal growth cones and acts as a ligand guiding specific growth cones by inhibiting their motility, through binding to the neuropilin-1/plexin-1 complex.
Therapeutic significance:
Semaphorin-3A's involvement in Hypogonadotropic hypogonadism 16 with or without anosmia highlights its potential as a target for therapeutic intervention. Understanding the role of Semaphorin-3A could open doors to potential therapeutic strategies for treating disorders related to olfactory system development and puberty regulation.